善裕集團控股(08245.HK)擬折讓約23.53%配售最多1.72億股 淨籌577萬港元
格隆匯4月12日丨善裕集團控股(08245.HK)公吿,於2024年4月12日,公司與配售代理訂立配售協議。根據配售協議,配售代理同意為及代表公司按每股配售股份0.034港元價格盡力向不少於六名獨立承配人配售最多172,350,000股新股份。配售價每股配售股份0.034港元。配售價較於2024年4月12日(即配售協議日期)於GEM收市報價每股0.042港元折讓約23.53%;配售股份最高數目佔公司經配售事項擴大全部已發行股本約16.67%。配售事項所得款項淨額約為577萬港元(假設配售股份獲悉數配售及扣除一切有關開支後),將用作集團業務營運運營資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.